Nimotuzumab
Information
- Drug Name
- Nimotuzumab
- Description
- Entry(CIViC)
- 2
CIViC
| Disease | Mutation | EL | ET | ED | CS | VO | TR | Pubmed | Links |
|---|---|---|---|---|---|---|---|---|---|
| brain glioma | EGFR VIII EGFR VIII | D |
Predictive
|
Supports
|
Sensitivity/Response | Somatic | 1 | 26778701 | Detail |
| esophagus squamous cell carcinoma |
EGFR OVEREXPRESSION ( ENST00000275493.7 ) EGFR OVEREXPRESSION ( ENST00000275493.7 ) |
B |
Predictive
|
Does Not Support
|
Sensitivity/Response | Somatic | 3 | 26459251 | Detail |
Annotation
| Description | Associated Genes | Associated Variants | Sensitivity | Supported | Source | Links |
|---|---|---|---|---|---|---|
| Two human glioma cell lines (U87MG or LNZ308) over... | EGFR | EGFR VIII EGFR VIII | Sensitivity | true | CIViC Evidence | detail |
| 55 tumor samples were analyzed for EGFR expression... | EGFR |
EGFR OVEREXPRESSION ( ENST00000275493.7 ) EGFR OVEREXPRESSION ( ENST00000275493.7 ) |
Sensitivity | false | CIViC Evidence | detail |
| NCT ID | Status | Phase | Summary | Start date | Completion date |
|---|---|---|---|---|---|
| NCT03620032 | Active, not recruiting | Phase 2 | Study of Re-irradiation at Relapse Versus RT and Multiple Elective rt Courses | November 2, 2015 | November 2, 2024 |
| NCT00957086 | Active, not recruiting | Phase 3 | Study of Post-Op Adjuvant Concurrent Chemo-RT With or Without Nimotuzumab for Head & Neck Cancer | August 13, 2009 | January 1, 2025 |
| NCT04207918 | Completed | Phase 2 | A Phase II Study of Chemoradiotherapy With Nimotuzumab in Unresectable Esophageal Cancer | November 14, 2019 | June 30, 2023 |
| NCT05278728 | Completed | Phase 1/Phase 2 | Phase IIa Study of Nimotuzumab to Treat Colorectal Cancer | July 2009 | December 2013 |
| NCT00753246 | Completed | Phase 3 | Nimotuzumab in Adults With Glioblastoma Multiforma | August 2007 | January 2012 |
| NCT02095119 | Completed | Phase 1/Phase 2 | A Monoclonal Antibody, Nimotuzumab, as Treatment for Recurrent or Metastatic Cervical Cancer | July 2008 | March 2014 |
| NCT00561691 | Completed | Nimotuzumab in Children With Intrinsic Pontine Glioma | April 2006 | January 2012 | |
| NCT00910117 | Completed | Phase 2 | Induction Chemotherapy With Nimotuzumab in Locally Advanced Head and Neck Squamous Cell Carcinoma (HNSCC) | May 2009 | December 2011 |
| NCT00950417 | Completed | Phase 1 | Nimotuzumab in Combination With Chemoradiation for Esophageal Cancer | July 2009 | November 2012 |
| NCT02947386 | Completed | Phase 1 | Nimotuzumab and Nivolumab in Treating Patients With Advanced Non-small Cell Lung Cancer | June 29, 2017 | September 8, 2022 |
| NCT01145170 | Completed | Phase 2 | Nimotuzumab and Radiotherapy in Pediatric Patients With Glioma | March 2011 | July 2014 |
| NCT04475016 | Completed | Phase 2 | TIP (Paclitaxel + Ifosfamide + Cisplatin) Combined With Nimotuzumab & Triprilimab as Neoadjuvant Treatment in Locally Advanced Penile Cancer | August 12, 2020 | May 30, 2022 |
| NCT03025958 | Completed | Phase 2 | Radiation Plus Concurrent Nimotuzumab in Elderly Patients With Locoregionally Advanced Nasopharyngeal Carcinoma | March 13, 2017 | December 30, 2023 |
| NCT01249352 | Completed | Phase 2/Phase 3 | A Study of Chemoradiation Associated With Nimotuzumab as the Treatment of Locally Advanced Esophageal Cancer | January 2009 | November 2013 |
| NCT02591784 | Completed | Phase 2 | Nimotuzumab in Combination With Radiotherapy for Esophageal Cancer | November 2008 | December 2011 |
| NCT02577341 | Completed | Phase 2 | Nimotuzumab Combined With Chemoradiotherapy for Unresectable Locally Advanced Squamous Cell Lung Cancer | August 2015 | October 2020 |
| NCT00561990 | Completed | Phase 2/Phase 3 | Nimotuzumab in Adults With Pancreatic Cancer | September 2007 | January 2014 |
| NCT06363084 | Completed | A Retrospective Study for Nimotuzumab Plus Postoperative Adjuvant Chemotherapy for Resectable Pancreatic Cancer | May 1, 2016 | June 30, 2023 | |
| NCT01463605 | Completed | Phase 2 | Nimotuzumab Combined With Radiotherapy for Older Patients With Esophageal Cancer: a Single, Non-control Clinical Trial | June 2011 | February 2020 |
| NCT03388372 | Completed | Phase 2 | Nimotuzumab Plus Radiotherapy With Concomitant and Adjuvant Temozolomide for Cerebral Glioblastoma | August 18, 2010 | March 23, 2017 |
| NCT00702481 | Completed | Phase 2 | Study of Nimotuzumab and Cisplatin/Radiotherapy for Locally Advanced Head and Neck Squamous Cell Cancer | April 28, 2008 | September 3, 2019 |
| NCT04949503 | Completed | A Real-world Study of the Efficacy and Safety of Nimotuzumab in Combination With Chemoradiotherapy for LASCCHN | October 8, 2021 | April 30, 2023 | |
| NCT02370849 | Completed | Phase 2 | Cisplatin and S-1 With or Without Nimotuzumab in Untreated Advanced Gastric Adenocarcinoma | October 2009 | February 2015 |
| NCT02395016 | Completed | Phase 3 | A Study of Nimotuzumab Combinated With Gemcitabine in K-RAS Wild-type Locally Advanced and Metastatic Pancreatic Cancer | April 2015 | November 2021 |
| NCT06048913 | Enrolling by invitation | Phase 1 | Nimotuzumab Combined With Concurrent Chemoradiotherapy for Locally Advanced Treatment Esophageal Cancer in Old Age | July 1, 2022 | July 1, 2028 |
| NCT04678791 | Not yet recruiting | N/A | Nimotuzumab Combined With Chemoradiotherapy Versus Chemoradiotherapy for Local Advanced Cervical Squamous Cell Carcinoma | December 2020 | December 2025 |
| NCT06422156 | Not yet recruiting | Phase 2 | SBRT Combined With Nimotuzumab and Mono-chemotherapy in Locally Advanced Pancreatic Cancer | June 1, 2024 | June 1, 2026 |
| NCT06409429 | Not yet recruiting | Phase 2/Phase 3 | Nimotuzumab Combined With GX as Postoperative Adjuvant Therapy in Pancreatic Cancer | May 1, 2024 | May 30, 2027 |
| NCT06333821 | Not yet recruiting | Phase 3 | A Study of Nimotuzumab Plus Concurrent Chemoradiotherapy Sequential Maintenance Treatment for Cervical Carcinoma | April 1, 2024 | April 1, 2030 |
| NCT05316480 | Not yet recruiting | Phase 2 | Nimotuzumab in EGFR Highly Expressed Pancreatic Neuroendocrine Neoplasms | May 1, 2022 | December 30, 2026 |
| NCT05024019 | Not yet recruiting | Phase 2 | Nimotuzumab Combined With Radiotherapy in High-risk Patients With HNSCC Not Suitable for Cisplatin After Surgery | August 21, 2021 | August 21, 2025 |
| NCT04976478 | Not yet recruiting | Study of Nimotuzumab Combined With IMRT in Elder Patients With Cervical Squamous Cell Carcinoma | July 2021 | December 2026 | |
| NCT05717790 | Recruiting | N/A | Concurrent and Adjuvant Nimotuzumab Combined With Induction Chemotherapy Plus Chemoradiation in Nasopharyngeal Carcinoma | December 1, 2022 | November 30, 2027 |
| NCT05772208 | Recruiting | Phase 3 | Intensified Treatments for Patients With Locally Advanced Nasopharyngeal Carcinoma With Detectable EBV DNA After One Cycle GP Regime Neoadjuvant Chemotherapy | January 1, 2022 | January 1, 2028 |
| NCT06022276 | Recruiting | N/A | Nimotuzumab for EGFR-amplified Advanced Pan Solid Tumors | December 1, 2022 | December 31, 2024 |
| NCT04821843 | Recruiting | Phase 3 | Neoadjuvant Treatment Modalities in Esophageal Cancer | January 1, 2002 | December 31, 2025 |
| NCT04821778 | Recruiting | Phase 3 | Chemoradiotherapy in Esophageal or Esophagogastric Junction Cancer | January 1, 2002 | December 31, 2025 |
| NCT06389760 | Recruiting | Phase 2 | Single-arm Study of Nimotuzumab Combined With mFOLFIRNIOX as Postoperative Adjuvant Therapy in Pancreatic Cancer | October 18, 2023 | September 30, 2026 |
| NCT06404840 | Recruiting | Phase 2 | Evaluating Nimotuzumab in Combination With AG Regimen for Pancreatic Cancer With Liver Metastases : A Prospective, Single-Arm, Phase II Study | May 6, 2022 | May 31, 2026 |
| NCT06405685 | Recruiting | Phase 2 | Nimotuzumab Plus AG in Pancreatic Cancer With Liver Metastasis | April 27, 2023 | October 30, 2025 |
| NCT06413017 | Recruiting | Phase 2 | Nimotuzumab Combined With ICIs for the Treatment of Advanced Liver Cancer After First Line Treatment Failure | August 31, 2023 | December 31, 2025 |
| NCT03574402 | Recruiting | Phase 2 | Phase II Umbrella Study Directed by Next Generation Sequencing | July 9, 2018 | December 30, 2024 |
| NCT03837808 | Recruiting | Phase 3 | Radiotherapy Plus Concurrent Nimotuzumab or Cisplatin in Stage II-III Nasopharyngeal Carcinoma | April 11, 2019 | February 11, 2024 |
| NCT00369447 | Terminated | Phase 1/Phase 2 | A Study of Nimotuzumab in Combination With External Radiotherapy in Non-Small Cell Lung Cancer | March 2009 | July 2011 |
| NCT00493857 | Terminated | Phase 2 | Study of Nimotuzumab and Irinotecan in Metastatic Colorectal Cancer | June 2007 | December 2008 |
| NCT00872482 | Terminated | Phase 2 | A Study of Nimotuzumab in Combination With Radiation Therapy in Patients With Brain Metastases | April 2009 | July 2011 |
| NCT01382745 | Terminated | Phase 2 | Nimotuzumab With Radiotherapy in the Treatment of Anal Canal Cancers | January 2012 | January 2022 |
| NCT01813253 | Terminated | Phase 3 | Phase 3 Study of Nimotuzumab and Irinotecan as Second Line With Advanced or Recurrect Gastric and Gastroesophageal Junction Cancer | May 13, 2013 | February 19, 2018 |
| NCT01074021 | Unknown status | Phase 3 | Nimotuzumab in Combination With Chemoradiation for Nasopharyngeal Cancer | October 2009 | August 2016 |
| NCT03554889 | Unknown status | Phase 1 | Immunotherapy of Advanced Cancer Using a Combination Nimotuzumab and NK Cells | August 1, 2018 | November 27, 2019 |
| NCT03557112 | Unknown status | Phase 2 | By Comparing TPF Induction Chemotherapy Combined With Nimotuzumab Concurrent Radiotherapy and Cisplatin Concurrent Radio-chemotherapy for Locally Advanced NPC | June 1, 2018 | December 1, 2021 |
| NCT03400592 | Unknown status | Phase 2 | Study of Nimotuzumab and Irinotecan as Second Line With Recurrent or Metastatic Gastric Adenocarcinoma | June 2015 | June 2018 |
| NCT02858206 | Unknown status | Phase 2 | Simultaneous Integrated Boost Radiotherapy and Concurrent Nimotuzumab or Chemotherapy for Esophageal Carcinoma | June 2016 | November 2021 |
| NCT03666221 | Unknown status | Phase 2 | Nimotuzumab for Recurrent Nasopharyngeal Carcinoma | November 1, 2014 | November 1, 2022 |
| NCT02705612 | Unknown status | Phase 2 | Phase II Clinical Trial of Concurrent Chemoradiotherapy Combined Nimotuzumab for Stage IIB-IVA Cervical Cancer | September 2015 | September 2018 |
| NCT03915132 | Unknown status | Phase 2 | Nimotuzumab Combined With VMAT in Elderly Patients With Nasopharyngeal Carcinoma | May 1, 2019 | May 1, 2022 |
| NCT02672241 | Unknown status | Phase 2 | Nimotuzumab in Combination With Radio-chemotherapy for the Treatment of Brainstem Tumor in Children | January 2016 | August 2019 |
| NCT04367909 | Unknown status | Phase 2 | A Study of TC(Docetaxel and Carboplatin) Regimen With or Without Nimotuzumab in Recurrent Metastatic Oral Squamous Cell Carcinoma | June 21, 2020 | December 1, 2022 |
| NCT02611700 | Unknown status | Phase 3 | Nimotuzumab in Combined With Paclitaxel and Cisplatin for Treatment of Metastatic Esophageal Squamous Cell Carcinoma | November 2015 | June 2019 |
| NCT02549261 | Unknown status | N/A | Nimotuzumab in Combination With Radiochemotherapy for Patients With Stage IIIA/IIIB Non-small Cell Lung Cancer | March 2011 | December 2015 |
| NCT02428764 | Unknown status | Phase 2 | Neoadjuvant Nimotuzumab Plus Gemcitabine and Carboplatin in Unresectable Stage III Squamous Cell Lung Carcinoma | April 2015 | October 2020 |
| NCT02409186 | Unknown status | Phase 3 | A Phase III Study of Nimotuzumab Plus Concurrent Chemoradiotherapy in Loco-regional Esophageal Squamous Cell Carcinoma | March 2015 | December 2021 |
| NCT04833205 | Unknown status | Phase 2 | Clinical Efficacy and Safety of EGFR-TKI Combined With Nimotuzumab in the Treatment of Leptomeningeal Metastases From Lung Cancer | April 19, 2021 | April 19, 2023 |
| NCT04882462 | Unknown status | Phase 2 | Sintilimab and Nimotuzumab Combined With Chemotherapy for the Treatment of R/M HNSCC. | May 1, 2021 | December 31, 2022 |
| NCT02395068 | Unknown status | Phase 1 | Pharmacokinetics Study of Nimotuzumab in Patients With Solid Tumors | November 2012 | December 2015 |
| NCT01516996 | Unknown status | Phase 2 | Safety and Efficacy Study of Nimotuzumab Plus Neoadjuvant and Concurrent Chemoradiotherapy to Treat Oropharynx and Hypopharynx Cancer | March 2012 | March 2018 |
| NCT01402180 | Unknown status | Phase 2/Phase 3 | Chemoradiation With or Without Nimotuzumab in Treating Esophageal Cancer Patients Who Suffer With Recurrence in Regional Lymph Nodes After Esophagectomy | December 2010 | December 2015 |
| NCT01336049 | Unknown status | Phase 2 | Nimotuzumab Plus Paclitaxel and Cisplatin as 1st Line Treatment for Esophageal Squamous Cell Cancer | March 2011 | |
| NCT01232374 | Unknown status | Phase 2 | Nimotuzumab in Combination With Chemoradiation for Local Advanced Esophageal Squamous Cell Carcinoma | September 2010 | January 2016 |
| NCT01180166 | Unknown status | Phase 2 | Combination of Nimotuzumab,Capecitabine and Radiotherapy for Inoperable or Recurrent Gastric Cancer | May 2010 | September 2013 |
| NCT03469531 | Unknown status | Phase 2 | Study of Nimotuzumab Combined With Concurrent Chemoradiotherapy for Locally Advanced Cervical Cancer | March 20, 2018 | December 30, 2021 |
| NCT02039791 | Unknown status | Phase 2 | Study of Nimotuzumab in Combination With Neoadjuvant Chemotherapy for Cervical Cancer | January 2013 | August 2016 |
| NCT01993784 | Unknown status | Phase 1/Phase 2 | Study of Nimotuzumab to Treat Esophageal Squamous Cell Carcinoma. | August 2013 | June 2014 |
| NCT01939054 | Unknown status | Phase 2 | Nimotuzumab Plus Docetaxel and Capecitabine Versus Docetaxel and Capecitabine in the Treatment of Breast Cancer Patients | September 2013 | September 2016 |
| NCT01899118 | Unknown status | Phase 2 | Nimotuzumab in Combination With Chemoradiation in Patients With Locally Advanced Rectal Cancer | April 2013 | |
| NCT02272699 | Withdrawn | Phase 2/Phase 3 | Neoadjuvant Treatment of Nimotuzumab With Chemotherapy or Radiotherapy in Resectable Esophageal Squamous Cell Carcinoma | November 2014 | December 2020 |
| NCT02041819 | Withdrawn | Phase 2 | Neoadjuvant Chemotherapy of Nimotuzumab Plus Nab-Paclitaxel in Squamous Cell Carcinoma of Esophagus | February 2014 | January 2017 |
| NCT01345084 | Withdrawn | Phase 3 | Study Comparing Radiation Therapy and Chemotherapy With or Without Nimotuzumab | November 2013 | November 2017 |
| NCT02034968 | Withdrawn | Phase 2 | Nimotuzumab Plus Nab-paclitaxel and Cisplatin in Treating Patients With Advanced Esophageal Carcinoma | February 2014 | January 2017 |
| NCT02011594 | Withdrawn | Phase 2 | Phase II Study of Maintenance Treatment of Nimotuzumab for Advanced Esophageal Carcinoma | January 2014 | February 2015 |
| NCT01301612 | Withdrawn | Phase 2 | Study of Nimotuzumab, Radiation Therapy and Cisplatin Versus Radiation Therapy and Cisplatin for Treatment of Stage IB e IVA UCC(CORUS) | January 2011 |